Bank of New York Mellon Corp grew its holdings in Accuray Incorporated (NASDAQ:ARAY) by 4.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 634,657 shares of the medical equipment provider’s stock after acquiring an additional 25,354 shares during the period. Bank of New York Mellon Corp’s holdings in Accuray were worth $2,538,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Accuray by 4.4% in the second quarter. Vanguard Group Inc. now owns 6,728,919 shares of the medical equipment provider’s stock worth $31,962,000 after buying an additional 281,789 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Accuray by 2.0% in the second quarter. Renaissance Technologies LLC now owns 4,391,000 shares of the medical equipment provider’s stock worth $20,857,000 after buying an additional 85,400 shares in the last quarter. PDT Partners LLC lifted its position in shares of Accuray by 60.5% in the second quarter. PDT Partners LLC now owns 156,500 shares of the medical equipment provider’s stock worth $743,000 after buying an additional 58,985 shares in the last quarter. Northern Trust Corp lifted its position in shares of Accuray by 4.5% in the second quarter. Northern Trust Corp now owns 1,048,694 shares of the medical equipment provider’s stock worth $4,981,000 after buying an additional 45,134 shares in the last quarter. Finally, Boston Partners lifted its position in shares of Accuray by 22.2% in the third quarter. Boston Partners now owns 2,276,184 shares of the medical equipment provider’s stock worth $9,105,000 after buying an additional 414,070 shares in the last quarter. Institutional investors and hedge funds own 78.86% of the company’s stock.
A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. downgraded Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 target price on the stock. in a research report on Wednesday, December 13th. BidaskClub downgraded Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Lake Street Capital assumed coverage on Accuray in a research report on Thursday, November 30th. They issued a “buy” rating and a $10.00 target price on the stock. Cowen reiterated a “buy” rating and issued a $9.00 target price on shares of Accuray in a research report on Friday, October 27th. Finally, Zacks Investment Research downgraded Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Accuray has an average rating of “Hold” and a consensus target price of $6.82.
Shares of Accuray Incorporated (ARAY) opened at $4.75 on Friday. The company has a debt-to-equity ratio of 2.44, a quick ratio of 0.92 and a current ratio of 1.48. Accuray Incorporated has a 52 week low of $3.60 and a 52 week high of $6.00. The firm has a market capitalization of $381.83, a P/E ratio of -13.97 and a beta of 1.29.
Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. The company had revenue of $91.00 million for the quarter, compared to analysts’ expectations of $88.26 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. equities analysts predict that Accuray Incorporated will post -0.23 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Accuray Incorporated (ARAY) Shares Bought by Bank of New York Mellon Corp” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/01/07/accuray-incorporated-aray-shares-bought-by-bank-of-new-york-mellon-corp.html.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.